{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T01:55:56Z","timestamp":1784339756352,"version":"3.55.0"},"reference-count":84,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0172414","type":"journal-article","created":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T18:34:43Z","timestamp":1488393283000},"page":"e0172414","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["Impact of vaccine herd-protection effects in cost-effectiveness analyses of childhood vaccinations. A quantitative comparative analysis"],"prefix":"10.1371","volume":"12","author":[{"given":"Marisa","family":"Holubar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Christina","family":"Stavroulakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P. A.","family":"Ioannidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Despina","family":"Contopoulos-Ioannidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,3,1]]},"reference":[{"issue":"3","key":"ref1","doi-asserted-by":"crossref","first-page":"174","DOI":"10.7326\/0003-4819-154-3-201102010-00007","article-title":"High-value, cost-conscious health care: concepts for clinicians to evaluate the benefits, harms, and costs of medical interventions","volume":"154","author":"DK Owens","year":"2011","journal-title":"Ann Intern Med"},{"issue":"19","key":"ref2","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1056\/NEJMp1110539","article-title":"The role of cost-effectiveness in U.S. vaccination policy","volume":"365","author":"JJ Kim","year":"2011","journal-title":"The New England Journal of Medicine"},{"key":"ref3","unstructured":"Advisory Committee on Immunization Practices (ACIP): Guidance for Health Economic Studies (<ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.cdc.gov\/vaccines\/acip\/committee\/guidance\/economic-studies.html\" xlink:type=\"simple\">http:\/\/www.cdc.gov\/vaccines\/acip\/committee\/guidance\/economic-studies.html<\/ext-link> Accessed 1\/2014."},{"issue":"4","key":"ref4","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2165\/00019053-200927040-00002","article-title":"Reviewing the cost effectiveness of rotavirus vaccination: the importance of uncertainty in the choice of data sources","volume":"27","author":"J Bilcke","year":"2009","journal-title":"PharmacoEconomics"},{"issue":"3","key":"ref5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2165\/11584930-000000000-00000","article-title":"Cost effectiveness of pneumococcal conjugate vaccination against acute otitis media in children: a review","author":"CW Boonacker","year":"2011","journal-title":"PharmacoEconomics"},{"issue":"8","key":"ref6","first-page":"1355","article-title":"Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination\u2014a review (2002\u20132006)","volume":"25","author":"P Beutels","year":"2007","journal-title":"Vaccine"},{"issue":"36","key":"ref7","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.1016\/j.vaccine.2009.05.061","article-title":"Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions","volume":"27","author":"I Ogilvie","year":"2009","journal-title":"Vaccine"},{"issue":"1","key":"ref8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/0272989X08324955","article-title":"Cost-effectiveness of rotavirus vaccination: exploring caregiver(s) and &quot;no medical care&apos;&apos; disease impact in Belgium","volume":"29","author":"J Bilcke","year":"2009","journal-title":"Medical Decision Making: an international journal of the Society for Medical Decision Making"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.vaccine.2007.11.070","article-title":"The cost-utility of rotavirus vaccination with Rotarix (RIX4414) in the Netherlands (Structured abstract)","author":"LM Goossens","year":"2008","journal-title":"Vaccine"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1741-7015-9-84","article-title":"Comparative review of three cost-effectiveness models for rotavirus vaccines in national immunization programs; a generic approach applied to various regions in the world","volume":"9","author":"MJ Postma","year":"2011","journal-title":"BMC Medicine"},{"issue":"3","key":"ref11","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1017\/S0266462304001096","article-title":"Assessing the economics of vaccination for Neisseria meningitidis in industrialized nations: a review and recommendations for further research","volume":"20","author":"D Getsios","year":"2004","journal-title":"Int J Technol Assess Health Care"},{"issue":"9","key":"ref12","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1073\/pnas.0915009107","article-title":"Vaccination with partial knowledge of external effectiveness","volume":"107","author":"CF Manski","year":"2010","journal-title":"PNAS"},{"issue":"2","key":"ref13","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.clinthera.2008.02.003","article-title":"The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine","volume":"30","author":"DJ Isaacman","year":"2008","journal-title":"Clinical Therapeutics"},{"issue":"34","key":"ref14","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1016\/j.vaccine.2014.03.017","article-title":"Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England","volume":"32","author":"AJ van Hoek","year":"2014","journal-title":"Vaccine"},{"issue":"7","key":"ref15","doi-asserted-by":"crossref","first-page":"e397","DOI":"10.1016\/S2214-109X(14)70224-4","article-title":"Population effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and non-typeable Haemophilus influenzae in Kilifi, Kenya: findings from cross-sectional carriage studies","volume":"2","author":"LL Hammitt","year":"2014","journal-title":"Lancet Glob Health"},{"issue":"20","key":"ref16","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1401914","article-title":"Effects of vaccination on invasive pneumococcal disease in South Africa","volume":"371","author":"A von Gottberg","year":"2014","journal-title":"The New England Journal of Medicine"},{"issue":"Suppl 2","key":"ref17","first-page":"S161","article-title":"Systematic review of the indirect effect of pneumococcal conjugate vaccine dosing schedules on pneumococcal disease and colonization","volume":"33","author":"JD Loo","year":"2014","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"ref18","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/INF.0000000000000279","article-title":"Direct and indirect effects of PCV13 on nasopharyngeal carriage of PCV13 unique pneumococcal serotypes in Massachusetts&apos; children","volume":"33","author":"AM Loughlin","year":"2014","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"ref19","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2165\/11535280-000000000-00000","article-title":"Methodological concerns with economic evaluations of meningococcal vaccines","volume":"28","author":"TL Kauf","year":"2010","journal-title":"PharmacoEconomics"},{"issue":"7385","key":"ref20","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/bmj.326.7385.365","article-title":"Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis","volume":"326","author":"ME Ramsay","year":"2003","journal-title":"BMJ"},{"issue":"2","key":"ref21","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1086\/649209","article-title":"Changes in Neisseria meningitidis disease epidemiology in the United States, 1998\u20132007: implications for prevention of meningococcal disease","volume":"50","author":"AC Cohn","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"3","key":"ref22","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/cid\/cir307","article-title":"Direct and indirect effects of rotavirus vaccination upon childhood hospitalizations in 3 US Counties, 2006\u20132009","volume":"53","author":"DC Payne","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"7","key":"ref23","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/infdis\/jir492","article-title":"Infant rotavirus vaccination may provide indirect protection to older children and adults in the United States","volume":"204","author":"BA Lopman","year":"2011","journal-title":"J Infect Dis"},{"issue":"10","key":"ref24","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jama.2010.250","article-title":"Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial","volume":"303","author":"M Loeb","year":"2010","journal-title":"JAMA"},{"issue":"13","key":"ref25","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.vaccine.2004.09.025","article-title":"Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children","volume":"23","author":"PA Piedra","year":"2005","journal-title":"Vaccine"},{"key":"ref26","unstructured":"Cost Effectiveness Analyses (CEA) Registry. The Center for the Evaluation of Value and Risk in Health and the Institute for Clinical Research and Health Policy Studies. Tufts Medical Center. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/research.tufts-nemc.org\/cear4\/\" xlink:type=\"simple\">https:\/\/research.tufts-nemc.org\/cear4\/<\/ext-link>. (Accessed 1\/2014)"},{"key":"ref27","unstructured":"WebPlot Digitizer; <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/arohatgi.info\/WebPlotDigitizer\/app\/\" xlink:type=\"simple\">http:\/\/arohatgi.info\/WebPlotDigitizer\/app\/<\/ext-link> (Accessed 1\/2014)."},{"key":"ref28","unstructured":"OANDA. Historical exchange rates (<ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.oanda.com\/currency\/historical-rates\/\" xlink:type=\"simple\">http:\/\/www.oanda.com\/currency\/historical-rates\/<\/ext-link>). Accessed 1\/2014)"},{"key":"ref29","unstructured":"Bureau of Labor Statistics. United States Department of Labor. CPI (Consumer Price Index) inflation calculator; <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.bls.gov\/data\/inflation_calculator.htm\" xlink:type=\"simple\">http:\/\/www.bls.gov\/data\/inflation_calculator.htm<\/ext-link> (accessed 3\/2016)"},{"issue":"52","key":"ref30","doi-asserted-by":"crossref","first-page":"9640","DOI":"10.1016\/j.vaccine.2011.10.038","article-title":"Pharmacoeconomic assessment of implementing a universal PCV-13 vaccination programme in the Valencian public health system (Spain)","volume":"29","author":"J D\u00edez-Domingo","year":"2011","journal-title":"Vaccine"},{"issue":"38","key":"ref31","doi-asserted-by":"crossref","first-page":"6686","DOI":"10.1016\/j.vaccine.2011.06.091","article-title":"Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines","volume":"29","author":"KR Tyo","year":"2011","journal-title":"Vaccine"},{"issue":"31","key":"ref32","doi-asserted-by":"crossref","first-page":"4963","DOI":"10.1016\/j.vaccine.2011.04.111","article-title":"Cost-effectiveness analysis of the 10- and 13-valent pneumococcal conjugate vaccines in Argentina","volume":"29","author":"A Urue\u00f1a","year":"2011","journal-title":"Vaccine"},{"issue":"Suppl 1","key":"ref33","doi-asserted-by":"crossref","first-page":"A7","DOI":"10.1016\/j.vaccine.2011.12.096","article-title":"Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011\u20132030","volume":"30","author":"DE Atherly","year":"2012","journal-title":"Vaccine"},{"issue":"1","key":"ref34","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1023\/B:HCMS.0000005397.93173.bb","article-title":"Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: a critical appraisal","volume":"7","author":"C Evans","year":"2004","journal-title":"Health Care Manag Sci"},{"issue":"2","key":"ref35","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1586\/14737167.8.2.165","article-title":"Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold","volume":"8","author":"SD Grosse","year":"2008","journal-title":"Expert Review of Pharmacoeconomics & Outcomes research"},{"key":"ref36","unstructured":"National Institute for Health and Clinical Excellence. Updated guide to the methods of technology appraisal\u2014June 2008. NICE."},{"issue":"9","key":"ref37","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"PJ Neumann","year":"2014","journal-title":"The New England Journal of Medicine"},{"key":"ref38","unstructured":"Cost effectiveness and strategic planning (WHO-CHOICE): Threshold values for intervention cost-effectiveness by Region. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.who.int\/choice\/costs\/CER_levels\/en\/\" xlink:type=\"simple\">http:\/\/www.who.int\/choice\/costs\/CER_levels\/en\/<\/ext-link>, August 14, 2015."},{"issue":"1","key":"ref39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0167-6296(96)00506-1","article-title":"Economic foundations of cost-effectiveness analysis","volume":"16","author":"AM Garber","year":"1997","journal-title":"Journal of Health Economics"},{"issue":"9","key":"ref40","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1080\/00365540802014872","article-title":"Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden","volume":"40","author":"A Bergman","year":"2008","journal-title":"Scand J Infect Dis"},{"issue":"28","key":"ref41","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1016\/j.vaccine.2012.04.028","article-title":"Cost-effectiveness of 13-valent pneumococcal conjugate vaccine in Switzerland","volume":"30","author":"PR Blank","year":"2012","journal-title":"Vaccine"},{"issue":"33","key":"ref42","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1016\/j.vaccine.2010.05.058","article-title":"Pharmacoeconomic evaluation of 10- and 13-valent pneumococcal conjugate vaccines","volume":"28","author":"AW Chuck","year":"2010","journal-title":"Vaccine"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1471-2334-12-101","article-title":"Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada","volume":"12","author":"SR Earnshaw","year":"2012","journal-title":"BMC Infect Dis"},{"issue":"11","key":"ref44","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1016\/j.vaccine.2009.12.070","article-title":"Cost-effectiveness of the CRM-based 7-valent pneumococcal conjugated vaccine (PCV7) in Argentina","volume":"28","author":"ND Giglio","year":"2010","journal-title":"Vaccine"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1186\/1471-2458-13-1025","article-title":"Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of Peru","volume":"13","author":"JA Gomez","year":"2013","journal-title":"BMC Public Health"},{"issue":"22","key":"ref46","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1016\/j.vaccine.2012.02.033","article-title":"Economic evaluation of vaccination programme of 7-valent pneumococcal conjugate vaccine to the birth cohort in Japan","volume":"30","author":"SL Hoshi","year":"2012","journal-title":"Vaccine"},{"issue":"18","key":"ref47","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1016\/j.vaccine.2007.01.088","article-title":"Enhanced decision support for policy makers using a web interface to health-economic models\u2014illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands","volume":"25","author":"GA Hubben","year":"2007","journal-title":"Vaccine"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/1471-2334-10-260","article-title":"Economic evaluation of pneumococcal conjugate vaccination in The Gambia","volume":"10","author":"SY Kim","year":"2010","journal-title":"BMC Infect Dis"},{"issue":"1","key":"ref49","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1478-7547-11-21","article-title":"A cost-effectiveness analysis of a 10-valent pneumococcal conjugate vaccine in children in six Latin American countries","volume":"11","author":"SG Mart\u00ed","year":"2013","journal-title":"Cost Eff Resour Alloc"},{"issue":"14","key":"ref50","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.vaccine.2004.08.051","article-title":"Pneumococcal pneumonia in the UK\u2014how herd immunity affects the cost-effectiveness of 7-valent pneumococcal conjugate vaccine (PCV)","volume":"23","author":"ED McIntosh","year":"2005","journal-title":"Vaccine"},{"issue":"31\u201332","key":"ref51","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1016\/j.vaccine.2004.05.003","article-title":"Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales","volume":"22","author":"A Melegaro","year":"2004","journal-title":"Vaccine"},{"issue":"45","key":"ref52","doi-asserted-by":"crossref","first-page":"8077","DOI":"10.1016\/j.vaccine.2011.08.050","article-title":"The potential cost-effectiveness of infant pneumococcal vaccines in Australia","volume":"29","author":"AT Newall","year":"2011","journal-title":"Vaccine"},{"issue":"6","key":"ref53","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/01.inf.0000222403.42974.8b","article-title":"Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects","volume":"25","author":"GT Ray","year":"2006","journal-title":"Pediatr Infect Dis J"},{"issue":"48","key":"ref54","doi-asserted-by":"crossref","first-page":"7634","DOI":"10.1016\/j.vaccine.2010.09.049","article-title":"Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States","volume":"28","author":"JL Rubin","year":"2010","journal-title":"Vaccine"},{"issue":"6","key":"ref55","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1590\/S1020-49892009001200007","article-title":"Estimating the cost-effectiveness of pneumococcal conjugate vaccination in Brazil","volume":"26","author":"G Vespa","year":"2009","journal-title":"Rev Panam Salud Publica"},{"issue":"29\u201330","key":"ref56","doi-asserted-by":"crossref","first-page":"5690","DOI":"10.1016\/j.vaccine.2006.04.042","article-title":"Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program","volume":"24","author":"T Wisl\u00f8ff","year":"2006","journal-title":"Vaccine"},{"issue":"23","key":"ref57","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.vaccine.2013.03.034","article-title":"Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact","volume":"31","author":"H1 Christensen","year":"2013","journal-title":"Vaccine"},{"issue":"21\u201322","key":"ref58","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1016\/S0264-410X(02)00161-5","article-title":"Economic analysis of the 1992\u20131993 mass immunization campaign against serogroup C meningococcal disease in Quebec","volume":"20","author":"P De Wals","year":"2002","journal-title":"Vaccine"},{"issue":"5","key":"ref59","doi-asserted-by":"crossref","first-page":"e65036","DOI":"10.1371\/journal.pone.0065036","article-title":"Meningococcal serogroup A, C, W\u2081\u2083\u2085 and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands","volume":"8","author":"H Hepkema","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"ref60","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/0272989X05284109","article-title":"Reassessing the cost-effectiveness of meningococcal serogroup C conjugate (MCC) vaccines using a transmission dynamic model","volume":"26","author":"CL Trotter","year":"2006","journal-title":"Med Decis Making"},{"issue":"48","key":"ref61","doi-asserted-by":"crossref","first-page":"6766","DOI":"10.1016\/j.vaccine.2012.09.025","article-title":"The cost-effectiveness of pentavalent rotavirus vaccination in England and Wales","volume":"30","author":"KE Atkins","year":"2012","journal-title":"Vaccine"},{"issue":"6","key":"ref62","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.vaccine.2012.11.071","article-title":"Estimating and comparing the clinical and economic impact of paediatric rotavirus vaccination in Turkey using a simple versus an advanced model","volume":"31","author":"M Bakir","year":"2013","journal-title":"Vaccine"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1741-7015-11-112","article-title":"Targeted rotavirus vaccination of high-risk infants; a low cost and highly cost-effective alternative to universal vaccination","volume":"11","author":"P Bruijning-Verhagen","year":"2013","journal-title":"BMC Med"},{"issue":"44","key":"ref64","doi-asserted-by":"crossref","first-page":"6121","DOI":"10.1016\/j.vaccine.2009.08.030","article-title":"The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe","volume":"27","author":"M Jit","year":"2009","journal-title":"Vaccine"},{"issue":"8","key":"ref65","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s40273-013-0060-7","article-title":"Understanding the cost-effectiveness of influenza vaccination in children: methodological choices and seasonal variability","volume":"31","author":"AT Newall","year":"2013","journal-title":"Pharmacoeconomics"},{"issue":"14","key":"ref66","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1016\/j.vaccine.2010.01.014","article-title":"Is it cost-effective to introduce rotavirus vaccination in the Dutch national immunization program?","volume":"28","author":"MJ Mangen","year":"2010","journal-title":"Vaccine"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1186\/1471-2458-11-462","article-title":"Consensus Group on Dutch Rotavirus Vaccination (CoRoVa-Group). Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model","volume":"11","author":"MH Rozenbaum","year":"2011","journal-title":"BMC Public Health"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1471-2334-13-54","article-title":"An update of &quot;Cost-effectiveness of rotavirus vaccination in the Netherlands: the results of a Consensus Rotavirus Vaccine model&quot;","volume":"13","author":"HA Tu","year":"2013","journal-title":"BMC Infect Dis"},{"issue":"6","key":"ref69","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jval.2011.03.005","article-title":"Cost-effectiveness of a recommendation of universal mass vaccination for seasonal influenza in the United States","volume":"14","author":"KM Clements","year":"2011","journal-title":"Value Health"},{"issue":"6","key":"ref70","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.vaccine.2012.12.010","article-title":"Cost-effectiveness of childhood influenza vaccination in England and Wales: Results from a dynamic transmission model","volume":"31","author":"RJ Pitman","year":"2013","journal-title":"Vaccine"},{"key":"ref71","article-title":"Disease Control Priorities in Developing Countries","author":"R Laxminarayan","year":"2006"},{"issue":"7543","key":"ref72","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/bmj.38737.607558.80","article-title":"Bias in published cost effectiveness studies: systematic review","volume":"332","author":"CM Bell","year":"2006","journal-title":"BMJ"},{"issue":"1","key":"ref73","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40273-013-0113-y","article-title":"Cost effectiveness of the new pneumococcal vaccines: a systematic review of European studies","volume":"32","author":"K van de Vooren","year":"2014","journal-title":"PharmacoEconomics"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1192\/bjp.183.6.498","article-title":"Quantitative analysis of sponsorship bias in economic studies of antidepressants","volume":"183","author":"CB Baker","year":"2003","journal-title":"Br J Psychiatry"},{"issue":"7482","key":"ref75","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/bmj.38285.482350.82","article-title":"Comparing estimates of cost effectiveness submitted to the National Institute for Clinical Excellence (NICE) by different organisations: retrospective study","volume":"330","author":"AH Miners","year":"2005","journal-title":"BMJ"},{"issue":"4","key":"ref76","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1586\/14737167.8.4.373","article-title":"Pneumococcal conjugate vaccine: review of cost-effectiveness studies in Australia, North America and Europe","volume":"8","author":"GT Ray","year":"2008","journal-title":"Expert Review of Pharmacoeconomics & Outcomes research"},{"issue":"1","key":"ref77","first-page":"3","article-title":"Cost effectiveness analysis of 13-valent pneumococcal conjugate vaccine in prevention of pneumococcal disease within the SUS scenario. Economic evaluation of pneumococcal vaccine","volume":"1","author":"CPR Souza","year":"2009","journal-title":"J Bras Econ Saude"},{"issue":"11","key":"ref78","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1016\/j.vaccine.2009.06.035","article-title":"WHO Guide for standardisation of economic evaluations of immunization programmes","volume":"28","author":"DG Walker","year":"2010","journal-title":"Vaccine"},{"issue":"4","key":"ref79","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hec.1481","article-title":"International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?","volume":"19","author":"T Shiroiwa","year":"2010","journal-title":"Health Econ"},{"key":"ref80","article-title":"Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a Eu.ropean Vaccine Economics Community","author":"B Ultsch","year":"2015","journal-title":"Pharmacoeconomics"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S1473-3099(10)70318-2","article-title":"New approaches to the assessment of vaccine herd protection in clinical trials","volume":"11","author":"J Clements","year":"2011","journal-title":"Lancet Infect. Dis"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S1473-3099(11)70090-1","article-title":"Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study","volume":"11","author":"E Miller","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1473-3099(15)70044-7","article-title":"Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study","volume":"15","author":"PA Waight","year":"2015","journal-title":"Lancet Infect. Dis"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1473-3099(14)71081-3","article-title":"Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance","volume":"15","author":"MR Moore","year":"2015","journal-title":"Lancet Infect. Dis"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0172414","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T03:55:39Z","timestamp":1540353339000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0172414"}},"subtitle":[],"editor":[{"given":"Diane Medved","family":"Harper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,3,1]]},"references-count":84,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,3,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0172414","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,1]]}}}